to build globally competitive businesses. They take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. They focus on delivering dramatic efficacy for patients in areas of high unmet need.

Syncona is aligned with two of the premium charitable funders in UK science, The Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in their business. They make a donation of 0.3% of Net Asset Value to a range of charities each year.